← Eichor
Condition: Progressive Glioblastoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Progressive Glioblastoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
Phase 1 · 1 location(s) · Beijing Biotech · NCT07480941ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV G
Phase 1 · 2 location(s) · Jonsson Comprehensive Cancer Center · NCT07089641Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
Phase 1 · 1 location(s) · Henry Ford Health System · NCT05686798Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT07468136Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progress
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT06815029Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of P
EARLY_Phase 1 · 1 location(s) · Mayo Clinic · NCT07076472Methimazole in Patients With Progressive Glioblastoma
Phase 2 · 1 location(s) · Case Comprehensive Cancer Center · NCT05607407PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
Phase 1/Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06161519A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas
Phase 2 · 1 location(s) · Case Comprehensive Cancer Center · NCT07003542GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma an
Phase 2 · 1 location(s) · Mayo Clinic · NCT07301268Intraarterial Carboplatin + Caelyx vs Intraarterial Carboplatin + Etoposide Phosphate for Progressing Glioblastoma
Phase 2 · 1 location(s) · Université de Sherbrooke · NCT06356883A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Gliobl
Phase 1 · 2 location(s) · University of Florida · NCT04573140A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma
Phase 1 · 3 location(s) · Tetragon Biosciences Ltd · NCT07464925Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurre
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT07544992A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma
Phase 1/Phase 2 · 16 location(s) · Debiopharm International SA · NCT05765812A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patients with Recurrent or Progre
Phase 1 · 1 location(s) · BeyondBio Inc. · NCT05769660Study of Pembrolizumab and M032 (NSC 733972)
Phase 1/Phase 2 · 1 location(s) · University of Alabama at Birmingham · NCT05084430First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma
Phase 1 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT07560865RNA-lipid Particle (RNA-LP) Vaccines for Recurrent/Progressive Medulloblastoma (MB)
Phase 1 · 1 location(s) · University of Florida · NCT07492316Sitagliptin in Recurrent/Progressive Grade 4 Glioma
Phase 1 · 1 location(s) · Kailin Yang, MD, PhD · NCT07541781A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma
Phase 1/Phase 2 · 11 location(s) · Guangzhou Virotech Pharmaceutical Co., Ltd. · NCT07093814Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
Phase 1 · 1 location(s) · Beijing Biotech · NCT07551336
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.